America is too dependent on drugs from China. Worst-case scenario could be disastrous
Strategic competition with Beijing demands clarity on American commitments and economic leverage.
The mainstream framing finally notices a real vulnerability, but it still treats it like a supply chain story instead of a strategic one. When Beijing controls so much of our active pharmaceutical ingredients, it is not just a “risk. ” It is leverage, and leverage gets used.
New Republican Times Editorial Board
U.S. pharmaceutical dependency on China poses urgent national security risks as Beijing dominates drug production and active pharmaceutical ingredients.
Original source:
Read at Fox NewsHow We See It
New Republican Times Editorial Board
The mainstream framing finally notices a real vulnerability, but it still treats it like a supply chain story instead of a strategic one. When Beijing controls so much of our active pharmaceutical ingredients, it is not just a “risk.” It is leverage, and leverage gets used.
What’s missing is accountability for how we got here. Years of outsourcing cheered on by corporate bean counters and waved through by regulators left us with brittle production and thin stockpiles. A serious response is not another white paper. It is domestic manufacturing capacity, faster approvals for trusted producers, and procurement rules that reward reliability over the lowest bid.
This is where national security meets public trust. In a crisis, shortages become panic, and panic erodes confidence in every institution.
The principle is simple: strategic independence in critical medicine is not protectionism, it is prudent self-government under the rule of law.
Commentary written with AI assistance by the New Republican Times Editorial Board.